Last reviewed · How we verify
NCT04680039
Early Warning of Intradialytic Hypotension in Hemodialysis Patients
trial testing Continuous monitoring in Hypotension of Hemodialysis in 150 participants. Completed in 15 March 2022.
15 February 2022
Quick facts
| Lead sponsor | Biobeat Technologies Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 15 January 2021 |
| Primary completion | 15 February 2022 |
| Estimated completion | 15 March 2022 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Continuous monitoring
Conditions studied
- Hypotension of Hemodialysis — all drugs for Hypotension of Hemodialysis →
Sponsor
Biobeat Technologies Ltd.
Who can join
Adults 18 to 120, any sex, with Hypotension of Hemodialysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the investigators will monitor patients undergoing hemodialysis treatment with a non-invasive wearable PPG-based device. Measurements will include blood pressure, heart rate, oxygen saturation, stroke volume, cardiac output, cardiac index and systemic vascular resistance, among others. The aim is to diagnose intradialytic hypotension more rapidly than with current noninvasive methods and prevent related poor outcomes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Continuous Monitoring of Advanced Hemodynamic Parameters during Hemodialysis Demonstrated Early Variations in Patients Experiencing Intradialytic Hypotension
Kolben Y, Gork I, Peled D, Amitay S, et al · · 2024
Verify or expand the search:
- PubMed search for NCT04680039
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypotension of Hemodialysis
Currently open trials in the same condition.
- NCT05297786 — Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease · Phase 2 · active not recruiting
Other Biobeat Technologies Ltd. trials
Trials by the same sponsor.
- NCT07240831 — Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring ( · NA · not yet recruiting
- NCT04955184 — Comparing Cardiac Output Measurements Using a Wearable, Wireless, Non-invasive PPG-Based Device to a Swan Ganz Catheter · completed
- NCT04635371 — Monitoring Patients With Acute Cardiac Disease Using a Wireless, Wearable, Non-invasive Monitor · completed
- NCT04548024 — Relation of Non-invasively Measured Parameters to Clinical Outcomes in CHF Patients · completed
- NCT04220359 — Early Identification of Clinical Deterioration Using a Wearable Monitoring Device · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04680039 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Biobeat Technologies Ltd.
- Last refreshed: 20 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04680039.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing